Evidence map›Paper›PMID 41889948›Full record

ArticlebioRxiv : the preprint server for biology2026

Identification of compounds that repress DUX4 expression in facioscapulohumeral muscular dystrophy.

Ning Chang, Hannah P Moore, Charis L Himeda, Terrence E O'Brien, William Thomas, Baback Roshanravan, Takako I Jones, Peter L Jones

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Ning ChangThe Department of Pharmacology, University of Nevada, Reno School of Medicine, 1664 N. Virginia St, Reno, NV 89557, USA.
Hannah P MooreThe Department of Pharmacology, University of Nevada, Reno School of Medicine, 1664 N. Virginia St, Reno, NV 89557, USA.
Charis L HimedaThe Department of Pharmacology, University of Nevada, Reno School of Medicine, 1664 N. Virginia St, Reno, NV 89557, USA.
Terrence E O'BrienAtomwise Inc., San Francisco, CA 94103, USA.
William ThomasThe Department of Pharmacology, University of Nevada, Reno School of Medicine, 1664 N. Virginia St, Reno, NV 89557, USA.
Baback RoshanravanDivision of Nephrology, University of California Davis, Genome Biomedical Sciences Facility, 451 Health Sciences Drive, Ste 5321, Sacramento, CA 95616, USA.
Takako I JonesThe Department of Pharmacology, University of Nevada, Reno School of Medicine, 1664 N. Virginia St, Reno, NV 89557, USA.
Peter L JonesThe Department of Pharmacology, University of Nevada, Reno School of Medicine, 1664 N. Virginia St, Reno, NV 89557, USA.

Funding

Mechanisms of DUX4 mediated FSHD pathologyR01AR062587 · NIAMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI JONES, PETER L · 2013 to 2024
$5.3M
NIAMS NIH HHS R01 AR062587
6 · The paper itself

Abstract

Facioscapulohumeral muscular dystrophy (FSHD) is caused by epigenetic dysregulation of the disease locus, leading to pathogenic misexpression of

Indexed as

AI-based drug screenD4Z4Double Homeobox 4drug developmentepigenetic regulationtargeting chromatin regulators

Identifiers

PMID41889948
PMCPMC13015533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.